glycopyrronium tosylate bulk supplier for pharma manufacturers

Glycopyrronium Tosylate 2.4% Suppliers & Bulk Manufacturers

Available Forms:

Available Strengths: 2.4%

Reference Brands: Qbrexza (USA)

Glycopyrronium Tosylate is a Derma Drugs product available as in strengths 2.4%. It corresponds to the reference brand Qbrexza (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Glycopyrronium tosylate, marketed under the brand name Qbrexza in the United States, is a topical anticholinergic medication indicated for the treatment of primary axillary hyperhidrosis. Primary axillary hyperhidrosis is a chronic condition characterized by excessive underarm sweating that is not related to heat or physical activity and can significantly affect daily life and social interactions.

Glycopyrronium tosylate works by blocking muscarinic acetylcholine receptors in the sweat glands, thereby reducing the stimulation responsible for excessive sweat production. It is formulated as a pre-moistened, single-use topical cloth that allows localized application directly to the affected area. This targeted delivery helps minimize systemic absorption while providing effective control of sweating.

The medication is approved for use in both adult and pediatric patients within the indicated age range, offering a non-invasive alternative to oral anticholinergic therapies or injectable treatments. Glycopyrronium tosylate is generally applied once daily and is designed for convenient, at-home use. Its topical formulation makes it a preferred option for patients seeking effective management of axillary hyperhidrosis with a reduced risk of widespread anticholinergic side effects.

Glycopyrronium Tosylate — third party manufacturing & bulk supply

Glycopyrronium Tosylate 2.4% is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Glycopyrronium Tosylate is a dosage form priced by order value, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Glycopyrronium Tosylate listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Glycopyrronium Tosylate →

Back to Listing

Frequently Asked Questions

Glycopyrronium tosylate is used for the treatment of primary axillary hyperhidrosis, a condition characterized by excessive underarm sweating in adults and pediatric patients of approved age.

Glycopyrronium tosylate is a synthetic anticholinergic compound derived from glycopyrronium, formulated as a tosylate salt to enhance stability and suitability for topical use.

The trade name of glycopyrronium tosylate is Qbrexza.

Qbrexza is manufactured and marketed by Journey Medical Corporation in the United States.

The complete generic name is glycopyrronium tosylate.

The brand name is Qbrexza.

Glycopyrronium tosylate finished dosage form for Qbrexza is manufactured in facilities approved for pharmaceutical production for the U.S. market, with manufacturing locations disclosed by the marketing authorization holder in regulatory filings.